European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. A

Go back to European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) Delayed: 28.13 -0.17 (0.6%)
Previous Close $28.30    52 Week High $37.39 
Open $27.97    52 Week Low $28.25 
Day High $28.16    P/E 17.05 
Day Low $27.83    EPS $1.65 
Volume 11,152,137       

Pfizer Inc. (NYSE: PFE) Delayed: 28.13 -0.17 (0.6%)
Previous Close $28.30    52 Week High $37.39 
Open $27.97    52 Week Low $28.25 
Day High $28.16    P/E 17.05 
Day Low $27.83    EPS $1.65 
Volume 11,152,137